Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models
Stefano Pierini,
Rashid Gabbasov,
Maria Cecilia Oliveira-Nunes,
Rehman Qureshi,
Alison Worth,
Shuo Huang,
Karan Nagar,
Crystal Griffin,
Lurong Lian,
Yumi Yashiro-Ohtani,
Kayleigh Ross,
Christopher Sloas,
Michael Ball,
Benjamin Schott,
Poonam Sonawane,
Linara Cornell,
Daniel Blumenthal,
Sotheavy Chhum,
Nicholas Minutolo,
Kerri Ciccaglione,
Lauren Shaw,
Isaac Zentner,
Hyam Levitsky,
Olga Shestova,
Saar Gill,
Bindu Varghese,
Daniel Cushing,
Sabrina Ceeraz DeLong,
Sascha Abramson,
Thomas Condamine and
Michael Klichinsky ()
Additional contact information
Stefano Pierini: Carisma Therapeutics Inc
Rashid Gabbasov: Carisma Therapeutics Inc
Maria Cecilia Oliveira-Nunes: Carisma Therapeutics Inc
Rehman Qureshi: Carisma Therapeutics Inc
Alison Worth: Carisma Therapeutics Inc
Shuo Huang: Carisma Therapeutics Inc
Karan Nagar: Carisma Therapeutics Inc
Crystal Griffin: Carisma Therapeutics Inc
Lurong Lian: Carisma Therapeutics Inc
Yumi Yashiro-Ohtani: Carisma Therapeutics Inc
Kayleigh Ross: Carisma Therapeutics Inc
Christopher Sloas: Carisma Therapeutics Inc
Michael Ball: Carisma Therapeutics Inc
Benjamin Schott: Carisma Therapeutics Inc
Poonam Sonawane: Carisma Therapeutics Inc
Linara Cornell: Carisma Therapeutics Inc
Daniel Blumenthal: Carisma Therapeutics Inc
Sotheavy Chhum: Carisma Therapeutics Inc
Nicholas Minutolo: Carisma Therapeutics Inc
Kerri Ciccaglione: Carisma Therapeutics Inc
Lauren Shaw: Carisma Therapeutics Inc
Isaac Zentner: Carisma Therapeutics Inc
Hyam Levitsky: Carisma Therapeutics Inc
Olga Shestova: University of Pennsylvania Perelman School of Medicine
Saar Gill: University of Pennsylvania Perelman School of Medicine
Bindu Varghese: Carisma Therapeutics Inc
Daniel Cushing: Carisma Therapeutics Inc
Sabrina Ceeraz DeLong: Carisma Therapeutics Inc
Sascha Abramson: Carisma Therapeutics Inc
Thomas Condamine: Carisma Therapeutics Inc
Michael Klichinsky: Carisma Therapeutics Inc
Nature Communications, 2025, vol. 16, issue 1, 1-16
Abstract:
Abstract We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition. In vivo, anti-HER2 CAR-M significantly reduce tumor burden, prolong survival, remodel the TME, increase intratumoral T cell and natural killer (NK) cell infiltration, and induce antigen spreading. CAR-M therapy protects against antigen-negative relapses in a T cell dependent fashion, confirming long-term anti-tumor immunity. In HER2+ solid tumors with limited sensitivity to anti-PD1 (aPD1) monotherapy, the combination of CAR-M and aPD1 significantly improves tumor growth control, survival, and remodeling of the TME in pre-clinical models. These results demonstrate synergy between CAR-M and T cell checkpoint blockade and provide a strategy to potentially enhance response to aPD1 therapy for patients with non-responsive tumors.
Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-024-55770-1 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55770-1
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-024-55770-1
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().